GOSS
Gossamer Bio, Inc.NASDAQHealthcare$0.37+1.37%ClosedMarket Cap: $86.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.64
P/S
1.67
EV/EBITDA
-1.53
DCF Value
$0.97
FCF Yield
-211.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.5%
Operating Margin
-352.2%
Net Margin
-351.5%
ROE
264.7%
ROA
-98.9%
ROIC
-155.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $13.8M | 98.4% | $-46.0M | $-47.2M | $-0.21 | — |
| FY 2025 | $48.5M | 97.9% | $-163.3M | $-170.4M | $-0.75 | — |
| Q3 2025 | $13.3M | 100.0% | $-49.1M | $-48.2M | $-0.21 | — |
| Q2 2025 | $11.5M | 100.0% | $-38.8M | $-38.3M | $-0.17 | — |
| Q1 2025 | $9.9M | 100.0% | $-36.8M | $-36.6M | $-0.16 | — |
| Q4 2024 | $9.4M | 100.0% | $-36.1M | $-33.0M | $-0.15 | — |
| FY 2024 | $114.7M | 100.0% | $-59.9M | $-56.5M | $-0.25 | — |
| Q3 2024 | $9.5M | 100.0% | $-33.9M | $-30.8M | $-0.14 | — |
| Q2 2024 | $95.8M | 100.0% | $52.1M | $49.2M | $0.21 | — |
| Q1 2024 | $0.00 | NaN% | $-42.0M | $-41.9M | $-0.19 | — |
| Q4 2023 | $0.00 | NaN% | $-49.0M | $-48.1M | $-0.21 | — |
| FY 2023 | $0.00 | NaN% | $-183.8M | $-179.8M | $-1.18 | — |